Odontostomatologic involvement in juvenile localised scleroderma of the face

Trainito, Sabina; Favero, Lorenzo; Martini, Giorgia; Pedersen, Thomas Klit; Favero, Vittorio; Herlin, Troels; Zulian, Francesco

doi:10.1111/j.1440-1754.2012.02435.x

Cited by 32 publications

(23 citation statements)

References 20 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nagy et al 17 offered an overall review, and many others have contributed. 12,16,[18][19][20][21][22] A tight, masklike, facial appearance, trismus owing to skin inflexibility and muscular atrophy with calcinosis, and thin atrophied lips with secondary microstomia are common. Tongue hypomobility and xerostomia and conjunctivitis from periductal fibrosis occur frequently.…”

mentioning

confidence: 99%

Scleroderma and the Temporomandibular Joint: Reconstruction in 2 Variants

MacIntosh

Shivapuja²,

Naqvi

2015

Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

mentioning

confidence: 99%

Scleroderma and the Temporomandibular Joint: Reconstruction in 2 Variants

MacIntosh

Shivapuja²,

Naqvi

2015

Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

“…Rapportées pour la première fois en 1968 [7], les complications dentaire de la SS restent jusqu’à nos jours mal connues et peu étudiées malgré leurs intérêts considérables aussi bien diagnostique que pronostique [6] et leur fréquence non négligeable [8]: 100% des patients ayant une sclérodermie juvénile de Trainito S. ont signalé au moins une complication odonto-stomatologique; les anomalies dentaires proprement dites ont été objectivé chez 63% d'entre eux [6]. …”

Section: Discussionunclassified

“…Les manifestations bucco-dentaires sont rarement étudiées et souvent négligées par les cliniciens malgré leur retentissement fonctionnel très marqué et l'handicap fonctionnel majeur qu'elles entrainent [6]. Nous étudierons, à travers cette observation, l'ensemble des atteintes bucco-dentaires au cours de cette connectivite ainsi que leurs particularités thérapeutiques et pronostiques.…”

Section: Introductionunclassified

Manifestations bucco-dentaires de la sclérodermie systémique

Bouomrani¹,

Rim²,

Sihem³

et al. 2013

Pan Afr Med J

View full text Add to dashboard Cite

Nous rapportons l'observation d'une jeune femme de 26 ans ayant une sclérodermie systémique diffuse présentant une atteinte bucco-dentaire complexe: microstomie, hyperplasie gingivale, parodontite, dépôts tartriques, caries multiples et chevauchement dentaire antéro-inférieur. Nous discuterons à travers cette observation les manifestations bucco-dentaires de cette connectivite qui sont loin d’être rares mais souvent négligées par les cliniciens malgré leur retentissement fonctionnel majeur. Il convient de surveiller régulièrement l’état bucco-dentaire chez tout patient sclérodermique afin de diagnostiquer précocement ces atteintes. Diagnostiquées à un stade tardif les complications bucco-dentaires de la sclérodermie seront très difficiles à traiter.

show abstract

“…5). This subtype might be accompanied by ocular [30, 31], neurological [1, 11, 32] and odontostomatologic [33–35] complications. Progressive hemifacial atrophy (Parry–Romberg syndrome) is characterized by diffuse unilateral subcutaneous atrophy of the face.…”

Section: Epidemiology Classification and Presentationmentioning

confidence: 99%

“…Odontostomatologic complications should be managed accordingly in cooperation with an oral maxillofacial surgeon and/or dentist [33–35]. Lastly, neurological manifestations consisting of seizures and headaches [145] may occur and referral to a neurologist could be considered to rule out central nervous system involvement [32, 146–150].…”

Section: Referral and Flow Chartmentioning

confidence: 99%

Morphea and Eosinophilic Fasciitis: An Update

et al. 2017

View full text Add to dashboard Cite

Morphea, also known as localized scleroderma, encompasses a group of idiopathic sclerotic skin diseases. The spectrum ranges from relatively mild phenotypes, which generally cause few problems besides local discomfort and visible disfigurement, to subtypes with severe complications such as joint contractures and limb length discrepancies. Eosinophilic fasciitis (EF, Shulman syndrome) is often regarded as belonging to the severe end of the morphea spectrum. The exact driving mechanisms behind morphea and EF pathogenesis remain to be elucidated. However, extensive extracellular matrix formation and autoimmune dysfunction are thought to be key pathogenic processes. Likewise, these processes are considered essential in systemic sclerosis (SSc) pathogenesis. In addition, similarities in clinical presentation between morphea and SSc have led to many theories about their relatedness. Importantly, morphea may be differentiated from SSc based on absence of sclerodactyly, Raynaud’s phenomenon, and nailfold capillary changes. The diagnosis of morphea is often based on characteristic clinical findings. Histopathological evaluation of skin biopsies and laboratory tests are not necessary in the majority of morphea cases. However, full-thickness skin biopsies, containing fascia and muscle tissue, are required for the diagnosis of EF. Monitoring of disease activity and damage, especially of subcutaneous involvement, is one of the most challenging aspects of morphea care. Therefore, data harmonization is crucial for optimizing standard care and for comparability of study results. Recently, the localized scleroderma cutaneous assessment tool (LoSCAT) has been developed and validated for morphea. The LoSCAT is currently the most widely reported outcome measure for morphea. Care providers should take disease subtype, degree of activity, depth of involvement, and quality-of-life impairments into account when initiating treatment. In most patients with circumscribed superficial subtypes, treatment with topical therapies suffices. In more widespread disease, UVA1 phototherapy or systemic treatment with methotrexate (MTX), with or without a systemic corticosteroid combination, should be initiated. Disappointingly, few alternatives for MTX have been described and additional research is still needed to optimize treatment for these debilitating conditions. In this review, we present a state-of-the-art flow chart that guides care providers in the treatment of morphea and EF.

show abstract

Odontostomatologic involvement in juvenile localised scleroderma of the face

Cited by 32 publications

References 20 publications

Scleroderma and the Temporomandibular Joint: Reconstruction in 2 Variants

Scleroderma and the Temporomandibular Joint: Reconstruction in 2 Variants

Manifestations bucco-dentaires de la sclérodermie systémique

Morphea and Eosinophilic Fasciitis: An Update

Contact Info

Product

Resources

About